Medicine and Dentistry
Cannabinoid 1 Receptor
100%
Diabetic Nephropathy
100%
Peroxisome Proliferator Activated Receptor
100%
Diabetes
83%
Diabetes Mellitus
66%
Ras
50%
Cannabinoid Receptor
50%
Rosiglitazone
33%
End Stage Renal Disease
33%
Fibrosis
33%
1 (2,4 Dichlorophenyl) 5 (4 Iodophenyl) 4 Methyl N (1 Piperidyl) 1h Pyrazole 3 Carboxamide
33%
Kidney Fibrosis
33%
Complementary DNA
33%
Receptor Modulation
16%
Cannabinoid 2 Receptor
16%
Oligonucleotide Therapy
16%
Cannabinoid 1 Receptor Agonist
16%
Glomerulus
16%
Glomerulosclerosis
16%
Laser Capture Microdissection
16%
Fibrogenesis
16%
Water-Electrolyte Imbalance
16%
Deterioration
16%
Drug Use
16%
Chronic Kidney Disease
16%
Transgenic Mouse
16%
Oligonucleotide
16%
Peroxisome Proliferator Activated Receptor Gamma
16%
Embryonic Stem Cell
16%
Illicit Drug
16%
Kidney Tissue
16%
Receptor Family
16%
2 (2 Amino 3 Methoxyphenyl)chromone
16%
Plasmid
16%
Signal Transduction
16%
RNA Interference
8%
RNAI
8%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetic Nephropathy
100%
Cannabinoid 1 Receptor
100%
Peroxisome Proliferator Activated Receptor
100%
Diabetes Mellitus
66%
Cannabinoid Receptor
50%
AM251
33%
Rosiglitazone
33%
Complementary DNA
33%
Fibrosis
33%
Kidney Fibrosis
33%
End Stage Renal Disease
33%
Receptor
16%
Transgenic Mouse
16%
Peroxisome Proliferator Activated Receptor Gamma
16%
Cannabinoid 1 Receptor Agonist
16%
Illicit Drug
16%
Deterioration
16%
Metabolic Disorder
16%
Chronic Kidney Failure
16%
Glomerulosclerosis
16%
2 (2 Amino 3 Methoxyphenyl)chromone
16%
Cannabinoid 2 Receptor
16%
Renal Diabetes
16%
Oligonucleotide
16%
Oligonucleotide
16%
Mouse
8%